BioCentury
ARTICLE | Emerging Company Profile

Quantum Immunologics: Going to School

October 5, 2009 7:00 AM UTC

Quantum Immunologics Inc. is developing an autologous dendritic cell therapy that it says applies lessons learned from Dendreon Corp.'s path through the clinic with Provenge sipuleucel-T.

Where Quantum says it is differentiated from other cancer immunotherapy companies is the antigen it uses to target the cancer cells, a cell surface receptor known as oncofetal antigen/immature laminin receptor protein (OFA/iLRP)...